Streetbeat News

FEMY

Femasys Inc.

https://www.femasys.com

Industry

Medical - Instruments & Supplies

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Open

1.12

Mkt cap

25M

Volume

107K

High

1.15

P/E Ratio

-1.45

52-wk high

2.40

Low

1.10

Div yield

N/A

52-wk low

0.73

China Natural Resources, Inc. (NASDAQ:CHNR) shares surged 63.5% in pre-market trading after agreeing to sell all outstanding shares of Precise Space-Time Technology Limited to Feishang Group Limited. Other pre-market gainers include FOXO Technologies Inc. (NYSE:FOXO), Aurora Acquisition Corp. (NASDAQ:AURC), Nano Labs Ltd (NASDAQ:NA), and Connexa Sports Technologies Inc. (NASDAQ:CNXA). On the other hand, Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) fell 22.4% in pre-market trading after announcing NYSE American has commenced delisting proceedings.

Portfolio Pulse from Lisa Levin

July 31, 2023 | 12:31 pm

During Friday's intraday session, several health care stocks experienced significant movements. Gainers included Reata Pharmaceuticals (RETA), Homology Medicines (FIXX), Bluejay Diagnostics (BJDX), Gracell Biotechnologies (GRCL), Pulse Biosciences (PLSE), and Larimar Therapeutics (LRMR). Losers included Tonix Pharmaceuticals (TNXP), Mallinckrodt (MNK), Intelligent Bio Solutions (INBS), G Medical Innovations (GMVD), Femasys (FEMY), and Marker Therapeutics (MRKR).

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 5:31 pm

The article lists the stocks that gained and lost the most during Friday's mid-day trading session. Among the gainers were Unique Fabricating, Reata Pharmaceuticals, and Bluejay Diagnostics, while the losers included Tonix Pharmaceuticals, Sleep Number Corporation, and Femasys Inc. Avantor shares fell by 9.9% due to worse-than-expected Q2 financial results.

Portfolio Pulse from Lisa Levin

July 28, 2023 | 5:07 pm

Several healthcare stocks experienced significant movement in Friday's pre-market session. Gainers included Reata Pharmaceuticals, Bluejay Diagnostics, SIGA Technologies, Homology Medicines, Creative Medical Tech, and Asensus Surgical. Losers included Tonix Pharmaceuticals, Bellerophon Therapeutics, Femasys, Telesis Bio, Mallinckrodt, and Titan Pharma.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 1:06 pm

Several stocks are experiencing significant pre-market movements. Coursera shares are up by 15.3% following better-than-expected Q2 sales results and an upgrade from Cantor Fitzgerald. Other gainers include Unique Fabricating, Greenbrook TMS, SIGA Technologies, Homology Medicines, Inpixon, AEye, Navidea Biopharmaceuticals, Intel Corporation, and Asensus Surgical. Losers include Tonix Pharmaceuticals, Sleep Number Corporation, Bellerophon Therapeutics, Mallinckrodt, Fresh Vine Wine, Enphase Energy, Femasys, Sigma Additive Solutions, Sweetgreen, and Yoshiharu Global.

Portfolio Pulse from Lisa Levin

July 28, 2023 | 11:57 am

Several healthcare stocks experienced significant movement in Thursday's after-market session. Gainers included SIGA Technologies, Homology Medicines, INVO Bioscience, AIM ImmunoTech, electroCore, and vTv Therapeutics. Losers included Tonix Pharmaceuticals, Femasys, Mettler-Toledo Intl, Inozyme Pharma, MyMD Pharmaceuticals, and Reshape Lifesciences.

Portfolio Pulse from Benzinga Insights

July 27, 2023 | 9:32 pm

US stocks fell on Thursday, with the Dow Jones dropping 0.59% and the NASDAQ falling 0.44%. McDonald's Corp (MCD) reported better-than-expected Q2 results, with sales growth of 13.6% YoY to $6.50 billion. Carmell Therapeutics Corporation (CTCX) shares rose 71% after announcing a merger with Axolotl Biologix. Femasys Inc. (FEMY) shares rose 128% after the US Patent and Trademark Office issued a Notice of Allowance for FemBloc. North American Construction Group Ltd. (NOA) shares rose 35% after better-than-expected Q2 results. Mersana Therapeutics, Inc. (MRSN) shares fell 78% after its UPLIFT clinical trial did not meet the primary endpoint. TPI Composites, Inc. (TPIC) shares fell 34% after lowering its 2023 forecast. Asensus Surgical, Inc. (ASXC) shares fell 39% after reporting a $10 million registered direct offering.

Portfolio Pulse from Lisa Levin

July 27, 2023 | 6:40 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Femasys (FEMY), Mallinckrodt (MNK), Cutera (CUTR), Evolus (EOLS), INVO Bioscience (INVO), and Talkspace (TALK) saw their stocks rise, with Femasys leading the gainers with a 146.9% increase. On the other hand, Mersana Therapeutics (MRSN), Asensus Surgical (ASXC), Biohaven (BHVN), Bluejay Diagnostics (BJDX), Armata Pharmaceuticals (ARMP), and icad (ICAD) saw their stocks fall, with Mersana Therapeutics leading the losers with a 78.3% decrease.

Portfolio Pulse from Benzinga Insights

July 27, 2023 | 5:31 pm

The article lists the stocks that have gained and lost the most in Thursday's mid-day session. Some of the top gainers include Femasys Inc., Ultralife Corporation, and Mallinckrodt plc, while the top losers include Mersana Therapeutics, Inc., Yellow Corporation, and Asensus Surgical, Inc. The reasons for the changes in stock prices range from better-than-expected quarterly results to reports of potential bankruptcy.

Portfolio Pulse from Lisa Levin

July 27, 2023 | 4:53 pm

Femasys Inc's shares are trading higher after the US Patent and Trademark Office issued a Notice of Allowance for a patent application related to the company's therapeutic product candidate, FemBloc. The patent strengthens Femasys' intellectual property position and coverage for FemBloc, a nonsurgical, non-implant, in-office solution for permanent birth control. The company expects the patent, when issued, to expire in 2039 at the earliest. Femasys' shares are up 108.80% at $0.80.

Portfolio Pulse from Vandana Singh

July 27, 2023 | 4:26 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.